Since ADVAIR DISKUS contains both fluticasone propionate and salmeterol, the mechanisms of action described below for the individual components apply to ADVAIR DISKUS. These drugs represent 2 classes of medications (a synthetic corticosteroid and a selective, long-acting beta-adrenergic receptor agonist) that have different effects on clinical and physiological indices.
The combination preparation fluticasone/salmeterol is a formulation containing fluticasone propionate and salmeterol xinafoate used in the management of asthma and chronic obstructive pulmonary disease (COPD). It is marketed by GlaxoSmithKline under various trade names including Advair (USA), Seretide (EU), Viani (Germany), Adoair (Japan), and ForAir (India).
Fluticasone, a corticosteroid, is the anti-inflammatory component of the combination, while salmeterol treats constriction of the airways. Together, they relieve the symptoms of coughing, wheezing and shortness of breath better than either fluticasone or salmeterol taken on its own.
The recommended regimen for asthma in individuals 12 years and older is one inhalation twice daily (morning and evening) approximately 12 hours apart. The lowest effective strength should be used and the maximum dose is 500/50 mcg twice daily. For children 4 to 11 years old the recommended treatment is one inhalation of 100/50 mcg twice daily.
Buy Advair in a Reliable International Online Pharmacy Free International Shipping
The common and minor side effects of this combination are those
of its individual drugs. For instance, the use of inhaled corticosteroids
is associated with oral candidiasis. Whilst the use of inhaled steroids
and long acting beta-adrenoceptor agonist (LABA) are recommended
in asthma guidelines for the resulting improved symptom control,
concerns have been raised that salmeterol may increase the small
risks of asthma deaths and this additional risk is not reduced with
the additional use of inhaled steroids.This seems to occur because
although LABAs relieve asthma symptoms, they also promote bronchial
inflammation and sensitivity without warning.
No deaths occurred in rats given an inhaled single-dose combination of salmeterol 3.6 mg/kg (approximately 290 and 140 times, respectively, the maximum recommended daily inhalation dose in adults and children on a mg/m2 basis) and 1.9 mg/kg of fluticasone propionate (approximately 15 and 35 times, respectively, the maximum recommended daily inhalation dose in adults and children on a mg/m2 basis).